Statin use in patients with liver disease
Pro Research Analysisby 
Searched over 200M research papers
Statin Use in Chronic Liver Disease: Safety and Efficacy
Statin Safety in Liver Disease Patients
Multiple studies have shown that statins are generally safe for patients with chronic liver disease (CLD), including those with nonalcoholic fatty liver disease (NAFLD) and compensated cirrhosis. Statin use does not significantly increase liver enzyme levels, and in some cases, alanine aminotransferase (ALT) levels are even lower in statin users compared to non-users with NAFLD . Despite these findings, statins remain under-prescribed in liver disease patients due to ongoing concerns about potential hepatotoxicity 39.
Statin Benefits: Reducing Liver Disease Progression and Complications
Statin use is associated with a lower risk of developing severe liver disease, including cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality. In patients with CLD, statins are linked to a 46% lower risk of hepatic decompensation and mortality, and a 27% lower risk of variceal bleeding or progression of portal hypertension 1245+2 MORE. Statin users with metabolic dysfunction-associated steatotic liver disease (MASLD) or NAFLD also experience reduced rates of liver-related events, HCC, decompensated cirrhosis, and all-cause mortality 4578.
Statins and Fibrosis Progression
Statin therapy appears to slow the progression of liver fibrosis. Patients with CLD who use statins are less likely to progress to higher fibrosis risk categories and more likely to improve their fibrosis scores over time . This effect is observed across various types of liver disease, including NAFLD and alcohol-related liver disease 57.
Cardiovascular Benefits in Liver Disease
Patients with liver disease, especially NAFLD, are at increased risk for cardiovascular disease. Statins effectively lower cholesterol and reduce cardiovascular events in this population, providing a dual benefit for both liver and heart health 36910. However, statin use is still lower than recommended, particularly in patients with advanced liver disease or decompensated cirrhosis 310.
Underutilization and Barriers to Statin Use
Despite strong evidence supporting statin safety and efficacy, only about 56% of NAFLD patients with a clear indication for statin therapy are prescribed these medications 310. Statin use decreases as liver disease advances, likely due to persistent safety concerns. Women and patients with more severe liver disease are less likely to receive statins, even when indicated .
Statins in Cirrhosis and Hepatocellular Carcinoma Prevention
Statins may help prevent the development and complications of cirrhosis, and reduce the risk of HCC in patients with CLD 1245+2 MORE. These benefits are seen in both observational studies and randomized controlled trials, although more prospective research is needed to confirm these findings 127.
Conclusion
Statins are safe and beneficial for most patients with chronic liver disease, including those with NAFLD, MASLD, and compensated cirrhosis. They reduce the risk of liver disease progression, complications, and mortality, and provide important cardiovascular protection. Despite this, statins remain underutilized in liver disease patients due to ongoing safety concerns. Increasing awareness among clinicians and patients about the safety and benefits of statins could improve outcomes for those with liver disease 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic
Statin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: a Systematic Review and Meta-analysis
Statin use is likely associated with lower risk of hepatic decompensation and mortality, and may reduce portal hypertension in patients with chronic liver diseases.
DOI
Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects
Statins may have beneficial effects on cirrhosis, portal hypertension, and HCC prevention in patients with chronic liver disease and cirrhosis, despite concerns about drug-induced liver injury.
Prevalence and factors associated with statin use among patients with non-alcoholic fatty liver disease in TARGET-NASH.
Statin use in patients with nonalcoholic fatty liver disease is higher in older patients with dyslipidemia or hypertension, but decreases as the disease progresses, likely due to safety concerns.
DOI
Statin use and liver-related prognosis among patients with MASLD
Statin use significantly reduces liver-related events and mortality risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), particularly in those with elevated alanine aminotransferase levels.
Statins are associated with a decreased risk of severe liver disease in individuals with non-cirrhotic chronic liver disease.
Statin use is associated with a decreased risk of severe liver disease in individuals with non-cirrhotic chronic liver disease, suggesting a potential disease-modifying role.
DOI